Specialty Pharmacy

Study finds exercise may improve chronic inflammation and cognitive impairment in the treatment of cancer patients.

Top news of the day from across the health care landscape.

ASCO is conducting a clinical trial to evaluate how different targeted cancer drugs work to find additional uses outside its FDA indication.

Generic drug pricing and medical marijuana access among pharmacy-related legislation at the state level.

Daclizumab (Zinbryta) treats adults with relapsing forms of multiple sclerosis.

Zinbryta is a long-acting injection that is self-administered by the patient every month.

Pharmacist was the only job on the list directly related to health care.

Patients with lung cancer who reported symptoms via Moovcare showed 1-year survival of 75%.

The highest retail prices for 23 different cancer drugs was found in the United States.

Adding temozolomide (Temodar) to chemoradiation reduced the risk of death by 33% in elderly glioblastoma patients.

Increased unemployment shows a negative impact on worldwide cancer mortality.

Aggressive treatment approach shows promise in children with high risk brain cancer.

Choosing Wisely recommendations have not substantially changed the care received by patients in the last 30 days of life.

Top news of the day from across the health care landscape.

Conditions such as multiple sclerosis, epilepsy and Parkinson’s disease may cause sexual dysfunction.

Denmark is close to eradicating HIV through a prevention approach.

Risk of developing breast cancer in women with a BRCA1 mutation may be reduced.

Study finds new technique may improve treatment of diabetes.

Fingolimod (Gilenya) has shown inconsistent improvements with disability in multiple sclerosis.

Various benefits associated with fingolimod (Gilenya) observed for relapsing-remitted multiple sclerosis.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Rovalpituzumab tesirine reduced tumor growth and even shrank tumors in some patients with small cell lung cancer.

Patients treated with chemotherapy and IMAB362 had a median overall survival of 16.7 months.

Bortezomib and dexamethasone slowed disease progression in patients with recurrent or refractory multiple myeloma.

Patients treated with atezolizumab had a longer median overall survival than patients treated with carboplatin-based regimens.

Association found between persistent immune activation, arterial inflammation, and plaque development in HIV

Postmenopausal women with early breast cancer showed a reduction in disease recurrence after 10 years of aromatase inhibitor therapy with letrozole.

Targeted treatment shows strongest efficacy in HER2 abnormalities.